400 related articles for article (PubMed ID: 11078282)
1. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy.
Boden WE; Pearson TA
Am J Cardiol; 2000 Mar; 85(5):645-50, A10. PubMed ID: 11078282
[TBL] [Abstract][Full Text] [Related]
2. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
3. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
5. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
Sprecher DL
Am J Cardiol; 2000 Dec; 86(12A):46L-50L. PubMed ID: 11374856
[TBL] [Abstract][Full Text] [Related]
6. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
Boden WE
Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126
[TBL] [Abstract][Full Text] [Related]
8. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
Chrysant SG; Ibrahim M
J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
[TBL] [Abstract][Full Text] [Related]
9. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Rubins HB; Robins SJ; Collins D; Fye CL; Anderson JW; Elam MB; Faas FH; Linares E; Schaefer EJ; Schectman G; Wilt TJ; Wittes J
N Engl J Med; 1999 Aug; 341(6):410-8. PubMed ID: 10438259
[TBL] [Abstract][Full Text] [Related]
10. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Isles CG; Paterson JR
QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
[TBL] [Abstract][Full Text] [Related]
11. 2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatment.
Bloomgarden ZT
Diabetes Care; 2005 Nov; 28(11):2795-802. PubMed ID: 16249560
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
Nyman JA; Martinson MS; Nelson D; Nugent S; Collins D; Wittes J; Fye CL; Wilt TJ; Robins SJ; Bloomfield Rubins H;
Arch Intern Med; 2002 Jan; 162(2):177-82. PubMed ID: 11802751
[TBL] [Abstract][Full Text] [Related]
13. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
14. Use of combination therapy for dyslipidemia: a lipid clinic approach.
Brown AS
Am J Cardiol; 2002 Nov; 90(10B):44K-49K. PubMed ID: 12467939
[TBL] [Abstract][Full Text] [Related]
15. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.
Boden WE
Am J Cardiol; 2000 Dec; 86(12A):19L-22L. PubMed ID: 11374850
[TBL] [Abstract][Full Text] [Related]
16. Beyond LDL-C--the importance of raising HDL-C.
Wierzbicki AS; Mikhailidis DP
Curr Med Res Opin; 2002; 18(1):36-44. PubMed ID: 11999145
[TBL] [Abstract][Full Text] [Related]
17. Achieving optimal lipid goals in patients with coronary artery disease.
Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of low HDL-cholesterol levels in the reduction of cardiovascular risk].
Stokić E; Marinkov J
Med Pregl; 2007; 60(3-4):145-50. PubMed ID: 17853726
[TBL] [Abstract][Full Text] [Related]
19. Treating mixed dyslipidemias: why and how.
Ballantyne CM
Clin Cardiol; 2001; 24(7 Suppl):II-6-9. PubMed ID: 11444652
[TBL] [Abstract][Full Text] [Related]
20. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials.
Sacks FM
Am J Cardiol; 2001 Dec; 88(12A):14N-18N. PubMed ID: 11788125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
